Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Contact the Firm Before the Deadline on September 22, 2026

A securities class-action lawsuit has been filed against PROCEPT BioRobotics on behalf of investors who purchased shares between February 28, 2024 and February 25, 2026, with a lead-plaintiff deadline of September 22, 2026. The complaint alleges PROCEPT's discount program caused handpiece orders to exceed procedures each quarter, allegedly inflating reported U.S. handpiece unit sales and revenue by pulling demand forward from future periods. The allegations pose potential litigation, disclosure, and demand-sustainability risks for PRCT, though no liability or damages have been established.

Analysis

The actionable issue is not litigation expense; it is whether PRCT’s consumable-revenue trajectory embeds channel inventory rather than procedure-backed utilization. If handpiece shipments have been running ahead of procedures, reported growth and gross-margin absorption may reverse simultaneously as distributors/providers work down inventory, creating a two-step de-rating: lower revenue estimates over the next 1-3 quarters and a lower multiple on reduced confidence in the installed-base monetization model.

The key diligence is to reconcile quarterly U.S. handpiece growth against disclosed Aquablation procedure growth, installed-base additions, and any change in discounting, payment terms, or deferred revenue. A widening shipment-to-procedure gap that does not normalize by the next earnings release would imply pulled-forward demand rather than benign stocking; management’s credibility on this KPI would then matter more than the eventual legal outcome. Plaintiffs' announcements alone are routine and do not independently establish liability.

Near term, lawsuit headlines can pressure PRCT liquidity and invite event-driven shorts, but the more material catalyst path is guidance risk at the next results and any reduction in consumables growth or gross-margin outlook. Competitors in robotic urology and BPH treatment could benefit if provider economics prove less compelling than PRCT has implied, though no direct read-through to BAC or ALV is evident; both appear unrelated tags rather than investable sympathy vehicles.

Contrarianly, the stock may already discount a meaningful portion of the allegation if the February disclosure reset expectations and procedure growth remains intact. A sustained procedure-growth rate consistent with prior guidance, stable handpiece reorder cadence, and no incremental discounting would falsify the inventory-overhang thesis and could produce a sharp short-covering rally given the litigation-driven narrative.

Key Decisions for Investors

• Do not initiate a position solely on the law-firm release; treat PRCT as a fundamental diligence watch until the next earnings call provides procedure volume, handpiece shipments, discounting, and inventory/channel commentary.
• For a 1-3 month bearish expression, consider a small PRCT short only if consensus revenue estimates still assume shipment growth materially above procedure growth; target a 15-25% downside on an estimate reset, with a hard risk stop on reaffirmed full-year guidance plus evidence that the shipment-procedure gap is narrowing.
• Prefer defined-risk downside via PRCT put spreads spanning the next earnings date if implied volatility remains below the expected post-results move; avoid naked puts because a credible utilization-data rebuttal could trigger a rapid reversal.
• Monitor the next quarterly handpiece-to-procedure relationship and gross-margin guidance as falsification markers: stable procedure growth, unchanged discounting, and maintained margin outlook should close bearish exposure rather than extrapolate litigation headlines.